ReviewTranslational andrology and urology2021
Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?
Review in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recent Advances in Multimodal Assessment Scoring Systems for Prostate Cancer: An Integrated Pathological and Imaging Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Ex-Vivo Prostate Evaluation of Fused-Data TREIT Using Only Biopsy-Probe Electrodes.IEEE transactions on bio-medical engineering · 2026Article
- Prostate Cancer Incidence, Mortality, and Survival in Switzerland.JAMA network open · 2026Article
- Intermittent androgen deprivation therapy for biochemical recurrence or prostate-specific antigen (PSA) persistence after radical prostatectomy: efficacy and prognostic factors.Translational andrology and urology · 2026Article
- Nested PCR detection of JC polyomavirus large T-antigen in prostate cancer tissues: a case-control analysis in a Sudanese population.Journal of the Egyptian National Cancer Institute · 2025Article
- Review
- Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimens.The Journal of pathology · 2025Article
- Article
- Review
- The Extracellular Matrix Stiffening: A Trigger of Prostate Cancer Progression and Castration Resistance?Cancers · 2022Review
- Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now.Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Gleason grading system, proposed by Dr. Donald F. Gleason in 1966, is one of the most important prognostic factors in men with prostate cancer (PCa). At consensus conferences held in 2005 and 2014, organized by the International Society of Urological Pathology (ISUP), the system was modified to reflect the current diagnostic and therapeutic approaches. In particular, in the 2014 Conference, it was recognized that there were weaknesses with the original and the 2005 ISUP modified Gleason systems. Based on the results of a research conducted by Prof. JI Epstein and his group, a new grading system was proposed by the ISUP in order to address some of such deficiencies: i.e., the five distinct Grade Groups (GGs). Since 2014, results of studies have been published by different groups and societies, including the Genitourinary Pathology Society (GUPS), giving additional support to the prognostic role of the architectural Gleason patterns and, in particular, of the GGs. A revised GG system, taking into account the percentage of Gleason pattern (GP) 4, cribriform and intraductal carcinoma, tertiary GP 5, and reactive stroma grade, has shown to have some advantages, however not ready for adoption in the current practice. The aim of this contribution was to review the major updates and recommendations regarding the GPs and GSs, as well as the GGs, trying to give an answer to the following questions: "How has the grade group system been used in the routine?" and "will the Gleason scoring system be replace by the grade groups?" We also discussed the potential implementation in the future of molecular pathology and artificial intelligence in grading to further define risk groups in patients with PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.